A Single and Repeat Dosing Study of the Safety, Drug Exposure and Clinical Activity of R-2487 in Patients with Rheumatoid Arthritis
Latest Information Update: 08 Jan 2025
At a glance
- Drugs R-2487 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Rise Therapeutics
Most Recent Events
- 06 Jan 2025 According to the Rise Therapeutics media release, the company has completed dose escalation enrollment stages and will now initiate the planned dose expansion stages, enrolling additional patients at fixed doses in this study.
- 29 Jan 2024 According to a Rise Therapeutics media release, first patient has been enrolled in this trial.
- 19 Oct 2023 Status changed from not yet recruiting to recruiting.